Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12872466 | 0.89 | LTA4H (0.43) | KDM1AKCNA3HRH3HRH2HRH1 | |
| SCHEMBL9911415 | 0.89 | LTA4H (0.43) | KDM1AKCNA3HRH3HRH2HRH1 | |
| SCHEMBL9911416 | 0.89 | LTA4H (0.43) | KDM1AKCNA3HRH3HRH2HRH1 | |
| SCHEMBL8501119 | 0.89 | HRH3 (0.43) | KDM1AKCNA3SPHK1MEN1ALDH1A1 | |
| SCHEMBL27359356 | 0.86 | MAOB (0.44) | KCNA3SPHK1HRH3HRH2HRH1 | |
| SCHEMBL22890977 | 0.84 | KCNA3 (0.38) | KDM1AKCNA3SPHK1MEN1ALDH1A1 | |
| SCHEMBL25467851 | 0.82 | KDM1A (0.46) | KDM1AWNT1GSK3BDYRK1A | |
| SCHEMBL22924215 | 0.82 | KDM1A (0.46) | KDM1AHRH3WNT1GSK3BDYRK1A | |
| SCHEMBL9911333 | 0.82 | CARM1 (0.47) | KDM1ACYP2D6KMT2AHRH3ACHE | |
| SCHEMBL12793976 | 0.81 | LTA4H (0.43) | KDM1ACYP2D6HRH3ACHEWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | KDM1A 1749/4885KCNA3 2945/4885SPHK1 515/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | KDM1A 954/4885KCNA3 1583/4885SPHK1 457/4885 |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | KDM1A 1749/4885KCNA3 2945/4885SPHK1 515/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | KDM1A 1749/4885KCNA3 2945/4885SPHK1 515/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | KDM1A 3869/4885KCNA3 4832/4885SPHK1 1672/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | KDM1A 776/4885KCNA3 4317/4885SPHK1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.